Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | PPARD | Q03181 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | PLAU | P00749 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22662253 | 0.89 | TSHR (0.44) | TSHRPPARDALOX15TP53TDP1 | |
| SCHEMBL18250731 | 0.80 | TSHR (0.55) | TSHRPPARDTP53TDP1CA12 | |
| SCHEMBL10389565 | 0.79 | TSHR (0.40) | TSHRPPARDALOX15TP53TDP1 | |
| SCHEMBL6142884 | 0.79 | TSHR (0.48) | TSHRPPARDALOX15TP53TDP1 | |
| SCHEMBL10388124 | 0.79 | PPARD (0.50) | TSHRPPARDALOX15TP53TDP1 | |
| SCHEMBL9605287 | 0.79 | TSHR (0.48) | TSHRPPARDALOX15TP53TDP1 | |
| SCHEMBL246813 | 0.78 | TSHR (0.52) | TSHRPPARDTP53TDP1CA12 | |
| SCHEMBL6051814 | 0.78 | TSHR (0.52) | TSHRPPARDTP53TDP1CA12 | |
| SCHEMBL282439 | 0.78 | TSHR (0.52) | TSHRPPARDTP53TDP1CA12 | |
| SCHEMBL5839773 | 0.77 | PPARD (0.56) | TSHRPPARDALOX15TP53TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109851632-A | A kind of preparation method of (carbamoylmethyl) diethyl phosphonate | 肇庆巨元生化有限公司 | 2019-06-07 | — | — | CN | claimed |
| EP-2212329-B1 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (1) | CHOONGWAE PHARMA CORP (KR) | 2014-07-30 | — | — | EP | claimed |
| EP-0483674-B1 | A process for producing an aliphatic amide and salts thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-12-28 | — | — | EP | claimed |
| US-5254733-A | Reacting 2-ethylcrotonaldehyde with willig reagent, then dinitrogen trioxide | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-10-19 | — | — | US | claimed |
| EP-0483674-A1 | A process for producing an aliphatic amide and salts thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-05-06 | — | — | EP | claimed |
| JP-5025111-A | — | — | None | — | — | JP | disclosed |
| WO-2025137285-A1 | ALKYNE SUBSTITUTED QUINAZOLINE DERIVATIVES AND USES THEREOF | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| EP-4219460-B1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA INC (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20250011324-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC., | 2025-01-09 | — | — | US | disclosed |
| US-12152026-B2 | Transglutaminase 2 (TG2) inhibitors | SITARI PHARMA, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| WO-2024175998-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | DUNAD THERAPEUTICS, LTD. (GB) | 2024-08-29 | — | — | WO | disclosed |
| CN-116685583-A | Pyrimidine compounds, compositions and pharmaceutical uses thereof | 缆图药品公司 | 2023-09-01 | — | — | CN | disclosed |
| US-4639450-A | LIVER DISORDERS | EISAI CO., LTD. (JP) | 1987-01-27 | — | — | US | disclosed |
| EP-0184753-A2 | Process for the preparation of alpha-aminoalkylphosphonic acids and alpha-aminoalkylphosphinic acids | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-06-18 | — | — | EP | disclosed |
| US-4456603-A | Polyprenylcarboxylic acid amides useful for treating liver dysfunction | EISAI CO., LTD. (JP) | 1984-06-26 | — | — | US | disclosed |
| US-4388237-A | NEUROLEPTIC, SEDATIVE, HYPNOTIC, ANALGESIC, ANTIDEPRESSANT | BASF AKTIENGESELLSCHAFT (DE) | 1983-06-14 | — | — | US | disclosed |
| US-4336192-A | ANALGESICS, SEDATIVES, ANTICHOLINERGIC AGENTS, ANTIEMETICS | BASF AKTIENGESELLSCHAFT (DE) | 1982-06-22 | — | — | US | disclosed |
| EP-0019172-A1 | 6-Substituted 11-alkylene-morphantridines, process for preparing them and pharmaceutical compositions containing them | BASF Aktiengesellschaft (DE) | 1980-11-26 | — | — | EP | disclosed |
| EP-0019157-A1 | 5,6-Dihydro-11-alkylene-morphanthridin-6-ones and process for their preparation | BASF Aktiengesellschaft (DE) | 1980-11-26 | — | — | EP | disclosed |
| US-3976620-A | Phosphorus containing amides flame retardants | HOOKER CHEMICALS & PLASTICS CORPORATION (US) | 1976-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12152026-B2 | Transglutaminase 2 (TG2) inhibitors | TGM2, TGM3, TGM1 | TSHR 2931/4885PPARD 4012/4885ALOX15 2593/4885 |
| US-20250011324-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | TGM2, TGM3, TGM1 | TSHR 2931/4885PPARD 4012/4885ALOX15 2593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.